Figure 8. Myb regulated miR-1252-5p/NEDD9 axis at the transcriptional level in PAC. (A) Schematic of the promoter regions of miR-1252 with potential Myb binding sites and the wild-type (wt) and mutant-type (mut) sites. (B, C) ChiP assay analyses of chromatin-bound antibody against Myb in PAC cells. IgG antibody was used as a negative control. (D, E) Dual-luciferase reporter assay in PAC cells. The relative luciferase activity was normalized to the Renilla luciferase activity. (F, G) qRT-PCR assay analyses of miR-1252-5p expression in PAC cells after transfection with the indicated vectors. (H, I) Western blot assay analyses of NEDD9 expression in PAC cells after transfection with the indicated vectors. J-K, The correlation of Myb mRNA with miR-1252-5p (J) or NEDD9 mRNA (K) in human PAC tissues (n = 102). CDS, coding sequence; PAC, pancreatic cancer; ns, not significant. Data are presented as mean ± SD from triplicate experiments. **P < 0.01; ***, P < 0.001.